abrdn plc Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL)

abrdn plc lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 872.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,807 shares of the medical research company’s stock after purchasing an additional 109,275 shares during the quarter. abrdn plc’s holdings in Charles River Laboratories International were worth $28,795,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. CNB Bank lifted its stake in Charles River Laboratories International by 9.7% during the 4th quarter. CNB Bank now owns 2,962 shares of the medical research company’s stock worth $700,000 after acquiring an additional 263 shares in the last quarter. Cornerstone Investment Partners LLC acquired a new position in Charles River Laboratories International during the 4th quarter worth about $324,000. Daiwa Securities Group Inc. lifted its stake in Charles River Laboratories International by 6.2% during the 4th quarter. Daiwa Securities Group Inc. now owns 4,549 shares of the medical research company’s stock worth $1,075,000 after acquiring an additional 265 shares in the last quarter. Everence Capital Management Inc. acquired a new position in Charles River Laboratories International during the 4th quarter worth about $378,000. Finally, Flputnam Investment Management Co. lifted its stake in Charles River Laboratories International by 7.5% during the 4th quarter. Flputnam Investment Management Co. now owns 61,768 shares of the medical research company’s stock worth $14,602,000 after acquiring an additional 4,293 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,932 shares of company stock valued at $3,693,663. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Argus raised their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Citigroup raised their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Finally, UBS Group raised their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Trading Up 2.5 %

NYSE:CRL opened at $232.56 on Tuesday. The firm has a market cap of $11.98 billion, a P/E ratio of 25.25, a PEG ratio of 1.78 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The stock’s 50 day simple moving average is $253.87 and its 200-day simple moving average is $221.91. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.98 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).